64 related articles for article (PubMed ID: 30216722)
1. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
[TBL] [Abstract][Full Text] [Related]
2. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB
Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
De Bondt M; Renders J; Struyf S; Hellings N
Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
[TBL] [Abstract][Full Text] [Related]
4. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis.
Yao H; Zhang J; Zheng Q; Zeng X; Huang H; Ling Z; Tang M; Chen Z; Wang W; He L
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300753. PubMed ID: 38442328
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
Himmelbauer MK; Bajrami B; Basile R; Capacci A; Chen T; Choi CK; Gilfillan R; Gonzalez-Lopez de Turiso F; Gu C; Hoemberger M; Johnson DS; Jones JH; Kadakia E; Kirkland M; Lin EY; Liu Y; Ma B; Magee T; Mantena S; Marx IE; Metrick CM; Mingueneau M; Murugan P; Muste CA; Nadella P; Nevalainen M; Parker Harp CR; Pattaropong V; Pietrasiewicz A; Prince RJ; Purgett TJ; Santoro JC; Schulz J; Sciabola S; Tang H; Vandeveer HG; Wang T; Yousaf Z; Helal CJ; Hopkins BT
J Med Chem; 2024 May; 67(10):8122-8140. PubMed ID: 38712838
[TBL] [Abstract][Full Text] [Related]
7. Novel Bruton's Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays.
Widstrom NE; Perez M; Pratt ED; Heier JL; Blankenhorn JF; Breidenbach L; Peterson H; Parker LL
ACS Chem Biol; 2022 Jun; 17(6):1328-1333. PubMed ID: 35653784
[TBL] [Abstract][Full Text] [Related]
8. Navigating a paradigm shift: Bruton's tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy.
Rao AG
Int Immunopharmacol; 2024 Jun; 135():112265. PubMed ID: 38781611
[No Abstract] [Full Text] [Related]
9. Development of 7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives Using QSARINS Tool as BTK Inhibitors for the Treatment of Rheumatoid Arthritis.
Patil SM; Asgaonkar KD; Magdum P; Chinde V; Edake A; Naik A
Antiinflamm Antiallergy Agents Med Chem; 2023; 22(4):236-249. PubMed ID: 38018179
[TBL] [Abstract][Full Text] [Related]
10. BTK inhibitor falters in multiple sclerosis trials.
Wood H
Nat Rev Neurol; 2024 May; 20(5):255. PubMed ID: 38594557
[No Abstract] [Full Text] [Related]
11. A Structure-Activity Investigation of the Fungal Metabolite (-)-TAN-2483B: Inhibition of Bruton's Tyrosine Kinase.
McCone JAJ; Teesdale-Spittle PH; Flanagan JU; Harvey JE
Chemistry; 2024 Apr; ():e202401051. PubMed ID: 38629656
[TBL] [Abstract][Full Text] [Related]
12. A quantitative mechanistic PK/PD model directly connects Btk target engagement and
Daryaee F; Zhang Z; Gogarty KR; Li Y; Merino J; Fisher SL; Tonge PJ
Chem Sci; 2017 May; 8(5):3434-3443. PubMed ID: 28507715
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Caldwell R; Liu-Bujalski L; Qiu H; Mochalkin I; Jones R; Neagu C; Goutopoulos A; Grenningloh R; Johnson T; Sherer B; Gardberg A; Follis AV; Morandi F; Head J
Bioorg Med Chem Lett; 2018 Nov; 28(21):3419-3424. PubMed ID: 30290988
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the cyclization strategy for new drug discovery.
Tang K; Wang S; Gao W; Song Y; Yu B
Acta Pharm Sin B; 2022 Dec; 12(12):4309-4326. PubMed ID: 36562004
[TBL] [Abstract][Full Text] [Related]
15. Boosting the predictive performance with aqueous solubility dataset curation.
Meng J; Chen P; Wahib M; Yang M; Zheng L; Wei Y; Feng S; Liu W
Sci Data; 2022 Mar; 9(1):71. PubMed ID: 35241693
[TBL] [Abstract][Full Text] [Related]
16. The Development of BTK Inhibitors: A Five-Year Update.
Tasso B; Spallarossa A; Russo E; Brullo C
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885993
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases.
Zhang D; Gong H; Meng F
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443496
[TBL] [Abstract][Full Text] [Related]
18. Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search.
Montaruli M; Alberga D; Ciriaco F; Trisciuzzi D; Tondo AR; Mangiatordi GF; Nicolotti O
Molecules; 2019 Jun; 24(12):. PubMed ID: 31207991
[TBL] [Abstract][Full Text] [Related]
19. Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Kawahata W; Asami T; Kiyoi T; Irie T; Taniguchi H; Asamitsu Y; Inoue T; Miyake T; Sawa M
J Med Chem; 2018 Oct; 61(19):8917-8933. PubMed ID: 30216722
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
